Last reviewed 2026-04-19 · How we verify

Oksykodonhydroklorid

Ostfold Hospital Trust · Phase 1 active Small molecule

Oksykodonhydroklorid is a Small molecule drug developed by Ostfold Hospital Trust. It is currently in Phase 1 development. Also known as: oxycodone.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Oksykodonhydroklorid
Also known as	oxycodone
Sponsor	Ostfold Hospital Trust
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of an Anterior Quadratus Lumborum Block vs. a TAP-block for Inguinal Hernia Repair (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Oksykodonhydroklorid CI brief — competitive landscape report
Oksykodonhydroklorid updates RSS · CI watch RSS
Ostfold Hospital Trust portfolio CI

Frequently asked questions about Oksykodonhydroklorid

What is Oksykodonhydroklorid?

Oksykodonhydroklorid is a Small molecule drug developed by Ostfold Hospital Trust.

Who makes Oksykodonhydroklorid?

Oksykodonhydroklorid is developed by Ostfold Hospital Trust (see full Ostfold Hospital Trust pipeline at /company/ostfold-hospital-trust).

Is Oksykodonhydroklorid also known as anything else?

Oksykodonhydroklorid is also known as oxycodone.

What development phase is Oksykodonhydroklorid in?

Oksykodonhydroklorid is in Phase 1.

Manufacturer: Ostfold Hospital Trust — full pipeline
Therapeutic area: All drugs in Other
Also known as: oxycodone

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing